Physician profile
Sana Jeffreys
NPI 1518057512
$2,989.88
in general payments reported to CMS, 2019-2025
35 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.41 · 2020: $16.57 · 2021: $240 · 2022: $725 · 2023: $1,398 · 2024: $374 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.67 |
| Education | $330.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $597.63 | 2020-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $232.59 | 2019-2023 | Darzalex, Imbruvica, Tecvayli |
| Astellas Pharma US INC | $219.60 | 2022-2023 | Xospata |
| Pharmacyclics LLC, An Abbvie Company | $199.37 | 2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $199.32 | 2022-2023 | Ninlaro |
| Amgen INC. | $184.09 | 2022-2023 | Kyprolis, Lumakras |
| Novartis Pharmaceuticals Corporation | $150.85 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $143.78 | 2023-2024 | Enhertu, Calquence |
| Genzyme Corporation | $117.19 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $92.57 | 2022-2024 | Libtayo |
| Gilead Sciences, INC. | $86.91 | 2021-2023 | Trodelvy |
| Seagen INC. | $85.23 | 2023 | Adcetris |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Array Biopharma INC | $66.48 | 2023-2024 | Mektovi, Lorbrena, Braftovi |
| Glaxosmithkline, LLC. | $58.67 | 2022-2023 | Shingrix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $50.80 | 2022-2023 | |
| Pfizer INC. | $42.71 | 2022 | |
| Merck Sharp & Dohme LLC | $36.78 | 2023-2024 | Keytruda, Lynparza |
| Genentech USA, INC. | $33.22 | 2022 | |
| Puma Biotechnology, INC. | $30.16 | 2023 | |
| Mirati Therapeutics, INC. | $28.99 | 2023 | Krazati |
| Celgene Corporation | $27.88 | 2022-2023 | Reblozyl |
| Abbvie INC. | $27.25 | 2025 | |
| Eisai INC. | $22.86 | 2023 | |
| Jazz Pharmaceuticals INC. | $22.16 | 2022 | |
| Novo Nordisk INC | $20.84 | 2023 | |
| Adc Therapeutics America, INC. | $20.45 | 2023 | |
| Incyte Corporation | $18.76 | 2023 | Jakafi |
| Stemline Therapeutics INC. | $15.88 | 2023 | Orserdu |
| Foundation Medicine, INC. | $15.78 | 2023 | |
| Taiho Oncology, INC. | $15.24 | 2023 | |
| Cti Biopharma Corp. | $15.04 | 2023 | Vonjo |
| Servier Pharmaceuticals LLC | $14.06 | 2023 | |
| Spectrum Pharmaceuticals INC. | $13.63 | 2023 | Rolvedon |
| Teva Pharmaceuticals USA, INC. | $13.12 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Jeffreys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.